Innovent Biologics Reports 50% Q1 Revenue Growth to $555M Driven by NRDL TKIs and Integrated Portfolio Strength

Innovent Biologics, Inc. (HKG: 1801) reported Q1 2026 product sales exceeding RMB 3.8 billion (USD 555 million), representing 50% year-over-year (YOY) growth. The robust performance was driven by rapid uptake of five newly reimbursed tyrosine kinase inhibitors (TKIs) and strong momentum from the company’s integrated product portfolio, including core assets Xinermei (mazdutide), Xinbiyue (tafolecimab), and Xinbimin (teprotumumab N01).

Financial Highlights – Q1 2026

Portfolio Performance Drivers

NRDL-Reimbursed TKIs

• Five tyrosine kinase inhibitors newly added to National Reimbursement Drug List (NRDL)
• Rapid market uptake demonstrating immediate commercial impact of reimbursement inclusion
• Oncology leadership increasingly evident through broad TKI portfolio penetration

Integrated Product Portfolio

• Xinermei (mazdutide): GLP-1/GCG dual agonist showing outstanding performance in metabolic disease segment
• Xinbiyue (tafolecimab): PD-L1/VEGF bispecific antibody contributing to oncology-immunology crossover success
• Xinbimin (teprotumumab N01): IGF-1R inhibitor for thyroid eye disease expanding into ophthalmology indications

Late-Stage Pipeline Advancement

Pipeline Significance

• Global Ambition: All three high-potential molecules progressing through international clinical development programs
• Target Diversity: Spanning immuno-oncology (IBI363), targeted ADC therapy (IBI343), and anti-angiogenesis (IBI324)
• Commercial Potential: Phase III assets represent next-generation revenue drivers beyond current portfolio

Therapeutic Area Expansion Strategy

Strategic Implications & Market Outlook

• Reimbursement Leverage: NRDL inclusion strategy proving highly effective for rapid commercial scale-up in China
• Portfolio Diversification: Successful expansion beyond oncology creates multiple growth vectors and reduces therapeutic concentration risk
• Global Development Capability: Advanced pipeline demonstrates sophisticated clinical trial execution across international sites
• Innovation Pipeline: Strong early-stage assets ensure sustainable long-term growth beyond current commercial products
• Competitive Positioning: Integrated approach combining domestic commercial strength with global development ambitions

Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, product adoption rates, clinical development timelines, and commercial potential. Actual results may differ due to risks including market competition, regulatory decisions, reimbursement dynamics, and clinical trial outcomes.-Fineline Info & Tech